The X Factor Continues for MYQ

|

Published 26-FEB-2021 09:46 A.M.

|

4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

MyFiziq Limited (ASX:MYQ), which has created proprietary technology that enables users to accurately check, track and assess their body dimensions, using only their smartphone, from the comfort of their home, is making all the right moves ahead of its NASDAQ listing, which is now inching closer to completion.

MYQ is forming a strong US team ahead of its NASDAQ listing and today announced it has signed two new board members, with high level experience in the health industry and capital markets.

The new Board members are Mr Edward Greissing Jr and Mrs Luisa Ingargiola.

Mr Greissing has a long highlight reel:

  • he is a Strategic Advisor and Senior Fellow with the Milken Institute;
  • worked with Global Governments addressing critical health and economic policy issues, including Health Innovation, Chronic Disease Prevention, Mental Health, Food and Nutrition, Pandemics and Health Emergencies, and Affordable Access and Reimbursement;
  • is a member of the Chimerix Board and served as the Nominations and Government Committee Chair and a member of the Compensation Committees.

Mr. Greissing works with global business and government leaders, investors, philanthropy, NGOs, and academic thought leaders to improve health outcomes for individuals and communities everywhere.

Before his time with the Milken Institute, he served as a member of the Executive Committee, Global Leadership Team, and Senior Vice President of Corporate Affairs at Sanofi.

Mr. Greissing has spent nearly four decades in the biopharmaceutical industry and led a wide range of Public Affairs and Global Corporate Affairs teams, first at the Upjohn Company and Pharmacia and later with Sanofi. His strategic approach to stakeholder management included new product launches and a freshness program for life cycle management resulting in improved patient outcomes, increased shareholder value, positive business results, and externally valued as a desired and trusted business partner.

Previously he served as President and Chief Executive Officer of Red Line Associates, a consulting firm with clients from the biopharmaceutical, device, food service, and financial industries.

Ms Ingargiola is equally talented:

  • resides on 5 NASDAQ boards as Audit Committee Chair;
  • has extensive experience in the Life and Health Insurance sector;
  • has a broad set of capital market skills and experience, ranging from strategy, IPOs, corporate governance, and M & A.

Ms Ingargiola has almost 20 years of experience in public company finance, compliance, capital markets oversight and mergers and acquisitions. She currently serves as Chief Financial Officer of a NASDAQ biotech firm and Audit Chair of several Public companies including AgEagle (NYSE: UAVS), Vision Marine (NASDAQ: VMAR) and Progress Acquisition Corporation (NASDAQ: PGRWU), a new SPAC that recently completed their IPO. She has served multiple public companies in various Officer and Director roles.

In terms of her skillset in relation to MYQ, Ms Ingargiola has helped guide the uplist or IPO of several companies to NASDAQ or the NYSE.

She has been involved in the successful execution of over $500 million in financing and merger transactions and has assisted companies navigate Board governance, merger diligence, regulatory compliance, financial controls and corporate strategy.

Mr Greissing will be a Non-Executive Director and Mrs Ingargiola a Non-Executive Director and Chair of the company’s Audit Committee.

MyFiziq CEO Vlado Bosanac is excited by the appointments saying, “I have always prided myself with the people I have around me and the skills they bring that challenge me as the CEO and Co-Founder of MyFiziq. It is so important to fill the skill and knowledge gap that is required to drive the company, its growth and shareholder value. I am extremely pleased to have Edward and Luisa joining the board of MyFiziq.

“As leaders in their respective fields, they will provide world-class guidance to our global offering and their networks. With a breadth of global expertise and relationships within Government, Institutional and Healthcare and capital markets.

“Our new board members are accomplished individuals that bring enormous personal brand equity and validation to the company and its offering.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X